AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback

Phase III Success:
AstraZeneca's Truqap (apivasertib) has shown significant improvement in radiographic progression-free survival (rPFS) in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC) when combined with abiraterone and androgen deprivation therapy (ADT)12.

Clinical Significance:
The study, CAPItello-281, demonstrated a "statistically significant and clinically meaningful improvement" in rPFS compared to the control group receiving abiraterone, ADT, and placebo12.

Safety Profile:
The Truqap combination was found to be well-tolerated, with adverse events consistent with the known toxicity profiles of the individual medicines1.

Future Plans:
AstraZeneca will present the findings at an upcoming medical congress and share the data with regulatory authorities worldwide1.

Redemption After Breast Cancer Failure:
This success comes after Truqap failed a late-stage study in metastatic triple-negative breast cancer, positioning AstraZeneca as a strong player in the prostate cancer space13.

Competitive Landscape:
The success of Truqap follows recent late-stage victories by other pharmaceutical companies in prostate cancer, including Pfizer's Talzenna and Xtandi, and Roche and Exelixis's Tecentriq and Cabometyx1.

Sources:

1. https://www.biospace.com/drug-development/astrazenecas-truqap-redeems-itself-with-phase-iii-prostate-cancer-win

2. https://www.clinicaltrialsarena.com/news/astrazenecas-truqap-combo-prostate/

3. https://endpts.com/astrazenecas-truqap-edges-closer-to-prostate-cancer-label-expansion-with-phase-3-win/